Scientific and Performance Evidence
Trudell Medical International has an enviable history of strong leadership in creating innovative medical devices that enhance the quality of life for people of all ages - all backed by science and clinical evidence.
A Real-World Study of 30-Day Exacerbation Outcomes in Chronic Obstructive Pulmonary Disease (COPD) Patients Managed with Aerobika OPEP
At 30 days, 18.5% of subjects (n = 405) using the Aerobika OPEP vs. 25.7% of controls had a moderate-to-severe exacerbation (a 28% reduction). The mean per patient cost of moderate-to-severe exacerbations in the Aerobika OPEP group was significantly lower than controls ($2,975 vs. $6,065).
Download
Impact of Oscillating Positive Expiratory Pressure Device Use on Post-Discharge Hospitalizations: A Retrospective Cohort Study Comparing Patients with COPD or Chronic Bronchitis Using the Aerobika® and Acapella® Devices
Patients receiving the Aerobika OPEP device, compared to the Acapella device, had lower rates of subsequent severe disease exacerbation and all-cause inpatient admission. This suggests that Aerobika OPEP device may be a beneficial add-on to usual care and that OPEP devices may vary in clinical effectiveness.
Download
Oscillating Positive Expiratory Pressure in Chronic Obstructive Pulmonary Disease
In COPD patients with chronic sputum production, PEQ and SGRQ scores, FVC and 6MWD improved post-oPEP. FEV1 and PEQ-ease-bringing-up-sputum improvements were related to improved ventilation providing mechanistic evidence to support OPEP use in COPD.
Download
Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID-19)
As patients with COVID-19 having chronic pulmonary diseases often have excessive airway secretions, expiration exercises should be performed in addition to general airway clearance exercises to facilitate sputum excretion and reduce the exhaustion due to coughing. In addition, auxiliary techniques, such as the application of oscillatory positive expiratory pressure (OPEP), can be utilized.
Download